Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal
Go back to Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 126.52 +2.12 (1.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.40 | 52 Week High | $118.49 | |||
| Open | $125.66 | 52 Week Low | $55.00 | |||
| Day High | $127.02 | P/E | N/A | |||
| Day Low | $123.57 | EPS | $-0.56 | |||
| Volume | 185,136 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1128.36 +4.45 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1123.91 | 52 Week High | $88.16 | |||
| Open | $1127.61 | 52 Week Low | $67.88 | |||
| Day High | $1138.79 | P/E | 261.19 | |||
| Day Low | $1124.15 | EPS | $4.32 | |||
| Volume | 651,794 | |||||
